Lingohr Asset Management GmbH Has $726,000 Holdings in BioNTech SE Sponsored ADR $BNTX

Key Points

• Lingohr Asset Management GmbH significantly reduced its stake in BioNTech SE by 84.1%, now holding only 6,822 shares, reflecting a valued position of approximately $726,000 in the company.
• Several hedge funds have been active with BioNTech, with Millennium Management LLC increasing its holdings by 252.5%, while GAMMA Investing LLC raised theirs by an astonishing 5,710.8% during recent quarters.
• BioNTech reported a revenue of $306.46 million for the latest quarter, showing a significant increase of 102.6% compared to the same period last year, despite missing EPS estimates.

Lingohr Asset Management GmbH decreased its position in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) by 84.1% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 6,822 shares of the company's stock after selling 36,209 shares during the period. BioNTech accounts for approximately 1.3% of Lingohr Asset Management GmbH's portfolio, making the stock its 29th biggest position. Lingohr Asset Management GmbH's holdings in BioNTech were worth $726,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Banque Cantonale Vaudoise acquired a new stake in shares of BioNTech in the first quarter worth about $36,000. Banque Transatlantique SA acquired a new stake in shares of BioNTech in the first quarter worth about $80,000. Costello Asset Management INC acquired a new stake in shares of BioNTech in the first quarter worth about $91,000. Goodman Advisory Group LLC acquired a new stake in shares of BioNTech in the first quarter worth about $105,000. Finally, NewEdge Advisors LLC acquired a new stake in shares of BioNTech in the first quarter worth about $167,000. Institutional investors and hedge funds own 15.52% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on BNTX shares. HC Wainwright reiterated a "buy" rating and issued a $136.00 price objective on shares of BioNTech in a research note on Monday, September 8th. Truist Financial reissued a "buy" rating and issued a $155.00 target price (up from $151.00) on shares of BioNTech in a report on Tuesday, June 3rd. Wells Fargo & Company set a $150.00 price objective on BioNTech and gave the stock an "overweight" rating in a report on Tuesday, August 5th. Morgan Stanley upped their price objective on BioNTech from $132.00 to $133.00 and gave the stock an "overweight" rating in a report on Thursday, July 10th. Finally, Leerink Partners set a $112.00 price target on BioNTech in a research note on Monday, June 2nd. Thirteen analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $135.80.

BioNTech Stock Up 1.4%

BNTX stock traded up $1.38 during trading hours on Tuesday, reaching $99.26. 1,171,157 shares of the stock were exchanged, compared to its average volume of 1,157,997. The firm's 50-day moving average is $108.30 and its 200-day moving average is $103.74. The company has a market cap of $23.86 billion, a price-to-earnings ratio of -62.04 and a beta of 1.39. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.61 and a quick ratio of 8.48. BioNTech SE Sponsored ADR has a 12 month low of $81.20 and a 12 month high of $131.49.

BioNTech (NASDAQ:BNTX - Get Free Report) last posted its quarterly earnings data on Monday, August 4th. The company reported ($1.60) EPS for the quarter, missing analysts' consensus estimates of ($1.41) by ($0.19). BioNTech had a negative return on equity of 1.84% and a negative net margin of 12.20%.The business had revenue of $306.46 million for the quarter, compared to analyst estimates of $161.26 million. During the same quarter in the prior year, the company earned ($3.36) earnings per share. The company's quarterly revenue was up 102.6% on a year-over-year basis. BioNTech has set its FY 2025 guidance at EPS. On average, equities research analysts expect that BioNTech SE Sponsored ADR will post -3.88 earnings per share for the current year.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.